Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
Bicycle Therapeutics (BCYC) Stock Price & Analysis
309 Followers
BCYC Stock Chart & Stats
Day’s Range$23.5 - $23.72
52-Week Range― - ―
Previous Close$23.62
Volume6.86K
Average Volume (3M)N/A
Market Cap
$1.01B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Aug 01, 2024EPS Estimate
-$1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$44.71Price Target Upside88.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bicycle Therapeutics News
PremiumCompany Announcements
Power Pedal: How Insider Voting Clout Could Sway Bicycle Therapeutics’ Future
PremiumCompany Announcements
Bicycle Therapeutics Announces Board Reshuffle and New Financial Agreement
PremiumCompany Announcements
Bicycle Therapeutics Welcomes Stephen Sands to BoardBulls Say, Bears Say
Bulls Say
Clinical Development ProgressBCYC announced continued progress with the Phase II/III Duravelo-2 study for BT8009 in metastatic bladder cancer, showing promise in the treatment landscape.
Financial PerformanceBicycle Therapeutics outperformed revenue expectations, reporting $19.5M, showcasing the company's strong financial health.
Product PipelineSignificant clinical data updates expected for BT8009 across multiple indications could lead to positive movements in the company's stock value.
Bears Say
Financial PerformanceResearch & Development expenses exceeded estimates, which could indicate higher costs than expected in the development of their products.
Product EfficacyDespite BT8009's comparable efficacy and improved safety profile, it demonstrated an ORR of 33% versus 68% in the Padcev + pembro Phase 3 trial.
Strategic ShiftsWithdrawal of BT5528 from the company’s financial models indicates a strategic shift to focus resources, potentially impacting the breadth of the development pipeline.
---
Ownership Overview
68.90% Insiders
5.99% Mutual Funds
6.16% Other Institutional Investors
18.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCYC FAQ
What was Bicycle Therapeutics Ltd’s price range in the past 12 months?
Currently, no data Available
What is Bicycle Therapeutics Ltd’s market cap?
Currently, no data Available
When is Bicycle Therapeutics Ltd’s upcoming earnings report date?
Bicycle Therapeutics Ltd’s upcoming earnings report date is Aug 01, 2024 which is in 84 days.
How were Bicycle Therapeutics Ltd’s earnings last quarter?
Bicycle Therapeutics Ltd released its earnings results on May 02, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$1.251 by $0.631.
Is Bicycle Therapeutics Ltd overvalued?
According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued.
Does Bicycle Therapeutics Ltd pay dividends?
Bicycle Therapeutics Ltd does not currently pay dividends.
What is Bicycle Therapeutics Ltd’s EPS estimate?
Bicycle Therapeutics Ltd’s EPS estimate is -$1.14.
How many shares outstanding does Bicycle Therapeutics Ltd have?
Currently, no data Available
What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?
Bicycle Therapeutics Ltd reported an EPS of -$0.62 in its last earnings report, beating expectations of -$1.251. Following the earnings report the stock price went up 2.025%.
Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?
Among the largest hedge funds holding Bicycle Therapeutics Ltd’s share is Baker Bros Advisors LP. It holds Bicycle Therapeutics Ltd’s shares valued at 32M.
---
Bicycle Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.71 (88.25% Upside)
$44.71 (88.25% Upside)
Blogger Sentiment
Bullish
BCYC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 627.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.35%
12-Months-Change
Fundamentals
Return on Equity
-56.21%
Trailing 12-Months
Asset Growth
27.60%
Trailing 12-Months
Company Description
Bicycle Therapeutics Ltd
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
---
BCYC Stock 12 Month Forecast
Average Price Target
$44.71
▲(88.25% Upside)
Technical Analysis
Best Analysts Covering BCYC
1 Year
1 Year Success Rate
12/17 ratings generated profit
1 Year Average Return
+40.79%
reiterated a buy rating 7 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +40.79% per trade.
---